Lilly Strattera Abuse Studies Spark Debate, But Lead To Clean Label
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly’s clean labeling on Strattera abuse potential appears to be the result of significant debate within FDA and extensive submissions by the company, review documents for the attention deficit/ hyperactivity disorder therapy suggest.